⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

January 1, 2021Metabolism and Target Organ DamageOpen Access

Precision medicine approaches in metabolic disorders and target organ damage: where are we now, and where are we going?

Amedeo Lonardo Christopher D. Byrne Giovanni Targher

View Full Paper

Ask AI

Bookmark

Share

Abstract

Metabolism and Target Organ Damage (M&TOD) is an international, peer-reviewed, open access scientific journal which provides an online platform for publication of clinical, basic and translational studies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lonardo et al. (2021) studied this question.

synapsesocial.com/papers/6a3f7edf901a52dbcb719a25 https://doi.org/10.20517/mtod.2021.03

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Pharmacologic management of metabolic and alcohol-associated liver diseaseMetabolism and Target Organ Damage · Tue,
2Lipids at the helm: a metabolic playbook for liver regenerationMetabolism and Target Organ Damage · Thu,
3Biological determinants and outcomes of sex discrepancies in MASLDMetabolism and Target Organ Damage · Fri,
4Sex and gender differences in MASLD: pathophysiological mechanisms, clinical implications, and future directionsMetabolism and Target Organ Damage · Thu,
5Short-term L-arabinose administration alleviates MASLD by remodeling gut microbiota and activating hepatic ATF5-dependent mitochondrial unfolded protein responseMetabolism and Target Organ Damage · Thu,

More from Metabolism and Target Organ Damage

Stage dependent management of sleeve gastrectomy leaks - a systematic review with proposed classification and management algorithmMon,
Intermittent fasting-induced amelioration of thyroid hormone sensitivity was associated with improvements in insulin sensitivity independent of weight loss in steatotic liver diseaseWed,
Association of exposure to phenols, pesticides, and phthalates with hepatic steatosis and MASLD in adolescents: the potential role of inflammation and lifestyle factorsTue,
Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver diseaseTue,
Cumulative metabolic, behavioral, and early-life factors for MASLD in Chinese children with validation in U.S. adolescentsTue,